NASD · Healthcare · Biotechnology · USA
Ligand Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Ligand Pharmaceuticals acquires and structures royalty streams from biopharmaceutical products in development or on the market, generating revenue from royalties on partner-sold medicines plus sales of platform technologies Captisol and NITRICIL. The company also receives contract revenues from licensing arrangements and milestone payments while maintaining a lean operational structure.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ligand Pharmaceuticals Inc stock.
Overvalued: intrinsic value $64.09 per share, market price $293.81, margin of safety -358.4% (as of 2026-11-17).
Discounting its cash flows at 10.4% (average of 2 methods) values the shares at $64.09; the price of $293.81 is 358% above that value, and 73% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
80 more in this industry show a wider margin of safety.
LGND is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 10.4% (average of 2 methods) values the shares at $64.09; the price of $293.81 is 358% above that value, and 73% of that value comes from beyond year five.
$64.09 per share (as of the 2026-11-17 close), against a market price of $293.81. That is a margin of safety of -358.4%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.